Jonathan P. May
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Jonathan P. May has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Shyh-Dar Li
Faculty of Pharmaceutical Sciences, UBC , Canada
13 shared publications Elijus Undzys
Drug Delivery and Formulation Group, Ontario Institute for Cancer Research, Toronto, M5G 0A3, Canada
9 shared publicationsEno Hysi
Department of Physics, Ryerson University, Toronto, M5 B 2K3, Canada; Institute for Biomedical Engineering, Science and Technology, Li Ka Shing Knowledge Institute, Keenan Research Center, St. Michael's Hospital, Toronto, M5 B 1T8, Canada
6 shared publications- Michael C. Kolios
Toronto Metropolitan University
6 shared publications - David M. Perrin
University of British Columbia 2036 Main Mall
5 shared publications Mark J. Ernsting
Drug Delivery and Formulation, Drug Discovery Program, Ontario Institute for Cancer Research, 101 College Street, Suite 800, Toronto, Ontario, Canada, M5G 0A3
5 shared publications
Latest Publications
- Open Access
- 22 September 2026
- Published by Royal Society of Chemistry (RSC) in RSC Pharmaceutics
- Vol. 3 (5) , 1253-1265
Ultrasound-triggered release of an active Wnt signalling agent (6-bromoindirubin-3-oxime) from perfluorocarbon nanodroplets
Ultrasound-triggered vaporisation of BIO-loaded perfluorobutane nanodroplets enables rapid release of active BIO, enhancing Wnt/TCF–LEF reporter signalling in cells and supporting spatially controlled delivery for regenerative medicine.
- 22 September 2026
- Published by Royal Society of Chemistry (RSC) in RSC Pharmaceutics
- Vol. 3 (5) , 1253-1265
Open AccessUltrasound-triggered release of an active Wnt signalling agent (6-bromoindirubin-3-oxime) from perfluorocarbon nanodroplets
Ultrasound-triggered vaporisation of BIO-loaded perfluorobutane nanodroplets enables rapid release of active BIO, enhancing Wnt/TCF–LEF reporter signalling in cells and supporting spatially controlled delivery for regenerative medicine.
- Open Access
- 1 December 2020
- Published by MDPI AG in Proceedings
- Vol. 78 (1) , 43
Development of a Nanodroplet Formulation for Triggered Release of BIO for Bone Fracture Healing
Impaired fracture healing impacts patients’ quality of life and imposes a financial burden on healthcare services. Up to 10% of bone fractures result in delayed/non-union fractures, for which new treatments are urgently required. However, systemic delivery of bone anabolic molecules is often sub-optimal and can lead to significant side effects. In this study, we developed ultrasound (US) responsive nano-sized vehicles in the form of perfluorocarbon nanodroplets (NDs), as a means of targeting delivery of drugs to localised tissues. We tested the hypothesis that NDs could stably encapsulate BIO (GSK-3β inhibitor), which could then be released upon US stimulation to activate Wnt signalling and induce ossification. NDs (~280 nm) were prepared from phospholipids and liquid perfluorocarbon and their stability and drug loading was studied by NTA (Nano Tracking Analysis) and HPLC. ND cytotoxicity was assessed in patient-derived bone marrow stromal cells (BMSCs) with Alamar Blue (24 h), and in vitro bioactivity of BIO-NDs was evaluated in a 3T3 Wnt-pathway reporter cell line with luciferase readout. To investigate the acoustic behaviour of NDs, 2% agarose (LM) containing NDs was injected into a bespoke bone fracture model (Sawbones) of various geometries and stimulated by US (1 MHz, 5% duty cycle, 1 MPa, 30 s), allowing the simultaneous capture of optical images and acoustic emissions. Femoral bone hole defects (1–2 mm) were made in WT-MF1 mice (age: 8–12 wks) and DiR-labelled NDs (100 µL, 109 NDs/mL, i.v.) were injected post-fracture to determine biodistribution by IVIS imaging. NDs were stable (4 and 37 °C) and retained >90% BIO until US was applied, which caused ~100% release. ND exposure up to a concentration of 109 NDs/mL showed no cytotoxicity (24 h). BIO-loaded NDs induced Wnt pathway activation in a dose dependent manner. Biodistribution of DiR-NDs in a femoral bone hole defect model in mice demonstrated increased localisation at the fracture site (~2-fold relative to that found in healthy mice or contralateral femurs at 48 h).
- 1 December 2020
- Published by MDPI AG in Proceedings
- Vol. 78 (1) , 43
Open AccessDevelopment of a Nanodroplet Formulation for Triggered Release of BIO for Bone Fracture Healing
Impaired fracture healing impacts patients’ quality of life and imposes a financial burden on healthcare services. Up to 10% of bone fractures result in delayed/non-union fractures, for which new treatments are urgently required. However, systemic delivery of bone anabolic molecules is often sub-optimal and can lead to significant side effects. In this study, we developed ultrasound (US) responsive nano-sized vehicles in the form of perfluorocarbon nanodroplets (NDs), as a means of targeting delivery of drugs to localised tissues. We tested the hypothesis that NDs could stably encapsulate BIO (GSK-3β inhibitor), which could then be released upon US stimulation to activate Wnt signalling and induce ossification. NDs (~280 nm) were prepared from phospholipids and liquid perfluorocarbon and their stability and drug loading was studied by NTA (Nano Tracking Analysis) and HPLC. ND cytotoxicity was assessed in patient-derived bone marrow stromal cells (BMSCs) with Alamar Blue (24 h), and in vitro bioactivity of BIO-NDs was evaluated in a 3T3 Wnt-pathway reporter cell line with luciferase readout. To investigate the acoustic behaviour of NDs, 2% agarose (LM) containing NDs was injected into a bespoke bone fracture model (Sawbones) of various geometries and stimulated by US (1 MHz, 5% duty cycle, 1 MPa, 30 s), allowing the simultaneous capture of optical images and acoustic emissions. Femoral bone hole defects (1–2 mm) were made in WT-MF1 mice (age: 8–12 wks) and DiR-labelled NDs (100 µL, 109 NDs/mL, i.v.) were injected post-fracture to determine biodistribution by IVIS imaging. NDs were stable (4 and 37 °C) and retained >90% BIO until US was applied, which caused ~100% release. ND exposure up to a concentration of 109 NDs/mL showed no cytotoxicity (24 h). BIO-loaded NDs induced Wnt pathway activation in a dose dependent manner. Biodistribution of DiR-NDs in a femoral bone hole defect model in mice demonstrated increased localisation at the fracture site (~2-fold relative to that found in healthy mice or contralateral femurs at 48 h).
- Open Access
- 1 March 2017
- Published by Elsevier in Photoacoustics
- Vol. 5, 25-35
Photoacoustic signal characterization of cancer treatment response: Correlation with changes in tumor oxygenation
- 1 March 2017
- Published by Elsevier in Photoacoustics
- Vol. 5, 25-35
Open AccessPhotoacoustic signal characterization of cancer treatment response: Correlation with changes in tumor oxygenation
- 1 December 2016
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 1-4
Cancer treatment response evaluation using photoacoustic signal envelop statistics: A preliminary study
Cancer is a major public health problem all over the world. It is currently the second leading cause of death in the United States, and is expected to surpass heart diseases as the leading cause of death in the next few years. To overcome this problem, researchers are discovering new treatments and developing imaging technologies that can aid in early detection of cancer. In this work, we investigate the use of signal envelope statistics to monitor and quantify structural changes in tissues during cell death. Ultrasound backscatter and photoacoustic data were obtained from three mice treated with, Hat-DOX, DOX and saline. The signal envelope statistics were examined by fitting the Rayleigh and Generalized Gamma distributions. The fit parameters showed sensitivity to structural changes in the cells in photoacoustic and ultrasound images. The results indicate that photoacoustic signal statistics can be potentially used to monitor structural changes within a tumor, raising the possibility of monitoring cancer therapy efficacy.
- 1 December 2016
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 1-4
Cancer treatment response evaluation using photoacoustic signal envelop statistics: A preliminary study
Cancer is a major public health problem all over the world. It is currently the second leading cause of death in the United States, and is expected to surpass heart diseases as the leading cause of death in the next few years. To overcome this problem, researchers are discovering new treatments and developing imaging technologies that can aid in early detection of cancer. In this work, we investigate the use of signal envelope statistics to monitor and quantify structural changes in tissues during cell death. Ultrasound backscatter and photoacoustic data were obtained from three mice treated with, Hat-DOX, DOX and saline. The signal envelope statistics were examined by fitting the Rayleigh and Generalized Gamma distributions. The fit parameters showed sensitivity to structural changes in the cells in photoacoustic and ultrasound images. The results indicate that photoacoustic signal statistics can be potentially used to monitor structural changes within a tumor, raising the possibility of monitoring cancer therapy efficacy.
- 3 November 2016
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 1-4
Photoacoustic radiofrequency spectroscopy for monitoring cancer treatment response
Frequency analysis of the photoacoustic (PA) signals was combined with functional PA estimations of tumor oxygenation to monitor the in-vivo response of a temperature sensitive liposome treatment. Mouse breast cancer tumors were imaged using the Vevo LAZR system (Fujifilm VisualSonics, Toronto, Canada) before treatment and 30 min/2h/5h/24h/7d post-treatment. Treatment consisted of an injection of either the liposome (HaT-DOX) or saline followed by heating of the tumor in a water bath for 1 hour at 43°C. The tumor oxygenation and the slope of the normalize power spectrum decreased by 22% and 45% at 750 nm, respectively as early as 30 minutes post-treatment. The combined analysis was able to differentiate responding mice from their non-responding counterparts and the control group. These results suggest that probing both structural (spectral slope) and functional (oxygen saturation) changes that occur during cancer treatment can aid in identifying treatment response.
- 3 November 2016
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- p. 1-4
Photoacoustic radiofrequency spectroscopy for monitoring cancer treatment response
Frequency analysis of the photoacoustic (PA) signals was combined with functional PA estimations of tumor oxygenation to monitor the in-vivo response of a temperature sensitive liposome treatment. Mouse breast cancer tumors were imaged using the Vevo LAZR system (Fujifilm VisualSonics, Toronto, Canada) before treatment and 30 min/2h/5h/24h/7d post-treatment. Treatment consisted of an injection of either the liposome (HaT-DOX) or saline followed by heating of the tumor in a water bath for 1 hour at 43°C. The tumor oxygenation and the slope of the normalize power spectrum decreased by 22% and 45% at 750 nm, respectively as early as 30 minutes post-treatment. The combined analysis was able to differentiate responding mice from their non-responding counterparts and the control group. These results suggest that probing both structural (spectral slope) and functional (oxygen saturation) changes that occur during cancer treatment can aid in identifying treatment response.
- Open Access
- 27 October 2016
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (10) , e0165345
Photoacoustic Imaging of Cancer Treatment Response: Early Detection of Therapeutic Effect from Thermosensitive Liposomes
Imaging methods capable of indicating the potential for success of an individualized treatment course, during or immediately following the treatment, could improve therapeutic outcomes. Temperature Sensitive Liposomes (TSLs) provide an effective way to deliver chemotherapeutics to a localized tumoral area heated to mild-hyperthermia (HT). The high drug levels reached in the tumor vasculature lead to increased tumor regression via the cascade of events during and immediately following treatment. For a TSL carrying doxorubicin (DOX) these include the rapid and intense exposure of endothelial cells to high drug concentrations, hemorrhage, blood coagulation and vascular shutdown. In this study, ultrasound-guided photoacoustic imaging was used to probe the changes to tumors following treatment with the TSL, HaT-DOX (Heat activated cytoToxic). Levels of oxygen saturation (sO2) were studied in a longitudinal manner, from 30 min pre-treatment to 7 days post-treatment. The efficacious treatments of HT-HaT-DOX were shown to induce a significant drop in sO2 (>10%) as early as 30 min post-treatment that led to tumor regression (in 90% of cases); HT-Saline and non-efficacious HT-HaT-DOX (10% of cases) treatments did not show any significant change in sO2 at these timepoints. The changes in sO2 were further corroborated with histological data, using the vascular and perfusion markers CD31 and FITC-lectin. These results allowed us to further surmise a plausible mechanism of the cellular events taking place in the TSL treated tumor regions over the first 24 hours post-treatment. The potential for using photoacoustic imaging to measure tumor sO2 as a surrogate prognostic marker for predicting therapeutic outcome with a TSL treatment is demonstrated.
- 27 October 2016
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (10) , e0165345
Open AccessPhotoacoustic Imaging of Cancer Treatment Response: Early Detection of Therapeutic Effect from Thermosensitive Liposomes
Imaging methods capable of indicating the potential for success of an individualized treatment course, during or immediately following the treatment, could improve therapeutic outcomes. Temperature Sensitive Liposomes (TSLs) provide an effective way to deliver chemotherapeutics to a localized tumoral area heated to mild-hyperthermia (HT). The high drug levels reached in the tumor vasculature lead to increased tumor regression via the cascade of events during and immediately following treatment. For a TSL carrying doxorubicin (DOX) these include the rapid and intense exposure of endothelial cells to high drug concentrations, hemorrhage, blood coagulation and vascular shutdown. In this study, ultrasound-guided photoacoustic imaging was used to probe the changes to tumors following treatment with the TSL, HaT-DOX (Heat activated cytoToxic). Levels of oxygen saturation (sO2) were studied in a longitudinal manner, from 30 min pre-treatment to 7 days post-treatment. The efficacious treatments of HT-HaT-DOX were shown to induce a significant drop in sO2 (>10%) as early as 30 min post-treatment that led to tumor regression (in 90% of cases); HT-Saline and non-efficacious HT-HaT-DOX (10% of cases) treatments did not show any significant change in sO2 at these timepoints. The changes in sO2 were further corroborated with histological data, using the vascular and perfusion markers CD31 and FITC-lectin. These results allowed us to further surmise a plausible mechanism of the cellular events taking place in the TSL treated tumor regions over the first 24 hours post-treatment. The potential for using photoacoustic imaging to measure tumor sO2 as a surrogate prognostic marker for predicting therapeutic outcome with a TSL treatment is demonstrated.
- 1 January 2016
- Published by Walter de Gruyter GmbH
Immune responses of therapeutic lipid nanoparticles
Nanoparticle-based drug delivery is an emerging technology for targeting therapeutics to the diseased site for enhanced therapy and reduced toxicity. A number of pharmaceutical products that involve nanotechnology have been approved for clinical use, and because of altered pharmacokinetics and biodistribution, their profiles of interaction with host cells and resulting toxicity are different from parent agents. This review focuses on the immune responses induced by therapeutic lipid nanoparticles. These immune responses can provoke toxicity, affect pharmacokinetics of the nanoparticles or induce therapeutic effect. This article begins with a general introduction on immune responses and innate and acquired immunity. Specific examples of therapeutic lipid nanoparticles inducing immune responses in each category are presented with detailed discussions on the mechanisms. Current guidelines for evaluating immune response of nanomedicines are summarized. Finally, perspectives and future directions are provided emphasizing mechanistic studies of immune reactions triggered by nanoparticles.
- 1 January 2016
- Published by Walter de Gruyter GmbH
Immune responses of therapeutic lipid nanoparticles
Nanoparticle-based drug delivery is an emerging technology for targeting therapeutics to the diseased site for enhanced therapy and reduced toxicity. A number of pharmaceutical products that involve nanotechnology have been approved for clinical use, and because of altered pharmacokinetics and biodistribution, their profiles of interaction with host cells and resulting toxicity are different from parent agents. This review focuses on the immune responses induced by therapeutic lipid nanoparticles. These immune responses can provoke toxicity, affect pharmacokinetics of the nanoparticles or induce therapeutic effect. This article begins with a general introduction on immune responses and innate and acquired immunity. Specific examples of therapeutic lipid nanoparticles inducing immune responses in each category are presented with detailed discussions on the mechanisms. Current guidelines for evaluating immune response of nanomedicines are summarized. Finally, perspectives and future directions are provided emphasizing mechanistic studies of immune reactions triggered by nanoparticles.
- 31 December 2015
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 27 (1) , 226-237
Synthesis of a Gemcitabine Prodrug for Remote Loading into Liposomes and Improved Therapeutic Effect
The chemotherapeutic gemcitabine was actively and stably loaded into lipid nanoparticles through the formation of a prodrug. Gemcitabine was chemically modified to increase the lipophilicity and introduce a weak base moiety for remote loading. Several derivatives were synthesized and screened for their potential to be good liposomal drug candidates for remote loading by studying their solubility, stability, cytotoxicity, and loading efficiency. Two morpholino derivatives of GEM (22 and 23) were chosen as the preferred prodrugs for this purpose as they possessed the best loading efficiencies (100% for drug-to-lipid ratio of 0.36 w/w). This is a considerable improvement over a passive loading strategy where typical loading efficiencies are on the order of ∼10–20% for a drug-to-lipid ratio of ∼0.01. Liposomes loaded with these two prodrugs were studied in an s.c. tumor model in vivo and showed improved therapeutic effect over free GEM (∼2-fold) and saline control (8- to 10-fold). This work demonstrates how chemical modification of a known hydrophilic drug can lead to improved loading, stability, and drug delivery in vivo.
- 31 December 2015
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 27 (1) , 226-237
Synthesis of a Gemcitabine Prodrug for Remote Loading into Liposomes and Improved Therapeutic Effect
The chemotherapeutic gemcitabine was actively and stably loaded into lipid nanoparticles through the formation of a prodrug. Gemcitabine was chemically modified to increase the lipophilicity and introduce a weak base moiety for remote loading. Several derivatives were synthesized and screened for their potential to be good liposomal drug candidates for remote loading by studying their solubility, stability, cytotoxicity, and loading efficiency. Two morpholino derivatives of GEM (22 and 23) were chosen as the preferred prodrugs for this purpose as they possessed the best loading efficiencies (100% for drug-to-lipid ratio of 0.36 w/w). This is a considerable improvement over a passive loading strategy where typical loading efficiencies are on the order of ∼10–20% for a drug-to-lipid ratio of ∼0.01. Liposomes loaded with these two prodrugs were studied in an s.c. tumor model in vivo and showed improved therapeutic effect over free GEM (∼2-fold) and saline control (8- to 10-fold). This work demonstrates how chemical modification of a known hydrophilic drug can lead to improved loading, stability, and drug delivery in vivo.
- 3 June 2015
- Published by Wiley in ChemBioChem
- Vol. 16 (10) , 1420-1425
Synthesis of a Cytotoxic Amanitin for Biorthogonal Conjugation
Alpha‐amanitin is an exceedingly toxic, naturally occurring, bicyclic octapeptide that inhibits RNA polymerase and results in cellular and organismal death. Here we report the straightforward synthesis of an amanitin analogue that exhibited near‐native toxicity. A pendant alkyne was readily installed to enable copper‐catalyzed alkyne–azide cycloaddition (CuAAC) to azido‐rhodamine and two azide‐bearing versions of the RGD peptide. The fluorescent toxin analogue entered cells and provoked morphological changes consistent with cell death. The latter two conjugates are as toxic as the parent alkyne precursor, which demonstrates that conjugation does not diminish toxicity. In addition, we showed that toxicity depends on a single diastereomer of the unnatural amino acid, dihydroxyisoleucine (DHIle), at position 3. The convenient synthesis of a heptapeptide precursor now provides access to bioactive amanitin analogues that may be readily conjugated to biomolecules of interest.
- 3 June 2015
- Published by Wiley in ChemBioChem
- Vol. 16 (10) , 1420-1425
Synthesis of a Cytotoxic Amanitin for Biorthogonal Conjugation
Alpha‐amanitin is an exceedingly toxic, naturally occurring, bicyclic octapeptide that inhibits RNA polymerase and results in cellular and organismal death. Here we report the straightforward synthesis of an amanitin analogue that exhibited near‐native toxicity. A pendant alkyne was readily installed to enable copper‐catalyzed alkyne–azide cycloaddition (CuAAC) to azido‐rhodamine and two azide‐bearing versions of the RGD peptide. The fluorescent toxin analogue entered cells and provoked morphological changes consistent with cell death. The latter two conjugates are as toxic as the parent alkyne precursor, which demonstrates that conjugation does not diminish toxicity. In addition, we showed that toxicity depends on a single diastereomer of the unnatural amino acid, dihydroxyisoleucine (DHIle), at position 3. The convenient synthesis of a heptapeptide precursor now provides access to bioactive amanitin analogues that may be readily conjugated to biomolecules of interest.
- 12 May 2015
- Published by Springer Nature in Pharmaceutical Research
- Vol. 32 (10) , 3261-3268
A Study of Liposomal Formulations to Improve the Delivery of Aquated Cisplatin to a Multidrug Resistant Tumor
This study was aimed at exploring the use of liposomes to deliver aquated cisplatin (ACP), a metabolite of CDDP, with increased potency and toxicity. Three liposomal formulations were compared for delivery of ACP to a multidrug resistant tumor. Three different liposomes (DMPC, DPPC and DSPC as the main lipid components) were loaded with ACP by the thin-film hydration method. In vitro drug release was assessed over 72 h at 37°C in PBS. The pharmacokinetics of free CDDP and the three ACP liposomes was determined using ICP-AES and their efficacy against EMT6-AR1 multidrug resistant murine breast tumor was compared. The DSPC formulation, composed of a C18 acyl chain lipid, exhibited the slowest drug release (~2%) after 72 h at 37°C, compared to the other two formulations with decreased carbon chain lengths (C16 and C14; 7 and 25% release respectively). The pharmacokinetic profile was improved with all liposomal formulations relative to free CDDP, with clearance reduced by 500-fold for DSPC, 200-fold for DPPC and 130-fold for DMPC. The DSPC formulation displayed the highest drug accumulation in the tumor with 2-fold, 3-fold and 100-fold increases compared to DPPC, DMPC and free CDDP respectively. The DSPC formulation significantly inhibited the EMT6-AR1 tumor growth by ~90%, while the other formulations displayed no statistically significant improved activity compared to saline. These results suggest that the DSPC liposomal formulation is a promising formulation for MDR tumor therapy over DMPC and DPPC formulations and free drug.
- 12 May 2015
- Published by Springer Nature in Pharmaceutical Research
- Vol. 32 (10) , 3261-3268
A Study of Liposomal Formulations to Improve the Delivery of Aquated Cisplatin to a Multidrug Resistant Tumor
This study was aimed at exploring the use of liposomes to deliver aquated cisplatin (ACP), a metabolite of CDDP, with increased potency and toxicity. Three liposomal formulations were compared for delivery of ACP to a multidrug resistant tumor. Three different liposomes (DMPC, DPPC and DSPC as the main lipid components) were loaded with ACP by the thin-film hydration method. In vitro drug release was assessed over 72 h at 37°C in PBS. The pharmacokinetics of free CDDP and the three ACP liposomes was determined using ICP-AES and their efficacy against EMT6-AR1 multidrug resistant murine breast tumor was compared. The DSPC formulation, composed of a C18 acyl chain lipid, exhibited the slowest drug release (~2%) after 72 h at 37°C, compared to the other two formulations with decreased carbon chain lengths (C16 and C14; 7 and 25% release respectively). The pharmacokinetic profile was improved with all liposomal formulations relative to free CDDP, with clearance reduced by 500-fold for DSPC, 200-fold for DPPC and 130-fold for DMPC. The DSPC formulation displayed the highest drug accumulation in the tumor with 2-fold, 3-fold and 100-fold increases compared to DPPC, DMPC and free CDDP respectively. The DSPC formulation significantly inhibited the EMT6-AR1 tumor growth by ~90%, while the other formulations displayed no statistically significant improved activity compared to saline. These results suggest that the DSPC liposomal formulation is a promising formulation for MDR tumor therapy over DMPC and DPPC formulations and free drug.